Clear Filter

Aug 03, 2022

FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition

IRVINE, Calif., Aug. 3, 2022 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUX™ XC for the improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition. 1

Jul 29, 2022

AbbVie Reports Second-Quarter 2022 Financial Results

NORTH CHICAGO, Ill., July 29, 2022 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2022.

Jul 29, 2022

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

NORTH CHICAGO, Ill., July 29, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective signs of inflammation, as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*1 

Jul 27, 2022

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Crohn's Disease

NORTH CHICAGO, Ill., July 27, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ®, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]) for the treatment of adult patients with moderately to severely active Crohn's disease.4,11

Jul 26, 2022

European Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative Colitis

NORTH CHICAGO, Ill., July 26, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the European Commission (EC) approved RINVOQ® (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.*

Jul 25, 2022

AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 Conference

Data analyses of onabotulinumtoxinA (BOTOX®) in adult patients with chronic migraine, cervical dystonia, overactive bladder, spasticity, and pediatric patients with neurogenic detrusor overactivity provide further insights on real-world utilization and long-term use

Jul 20, 2022

AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma

- Alliance will provide opportunity for AbbVie to further expand its diverse eye care portfolio and provide additional treatment options for glaucoma patients
- Collaboration further supports the role of MINIject® in the treatment of glaucoma and accelerates goal to bring MINIject to more patients globally
- Deal terms include a $60M upfront payment to iSTAR Medical
- iSTAR Medical to continue development and commercialization of the MINIject device up to completion of the U.S. PMA study

Jul 18, 2022

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

NORTH CHICAGO, Ill., July 18, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month. The application is supported by the pivotal Phase 3 ADVANCE and PROGRESS studies evaluating the safety, efficacy, and tolerability of atogepant in adult patients with episodic migraine and chronic migraine, respectively.1,2  

Jul 08, 2022

AbbVie to Host Second-Quarter 2022 Earnings Conference Call

NORTH CHICAGO, Ill., July 8, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2022 financial results on Friday, July 29, 2022, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website An archived edition of the session will be available later that day.

Jun 27, 2022

Approximately 15,000 AbbVie Employees to Volunteer Globally to Support Local Communities in Annual Week of Possibilities

– AbbVie's Week of Possibilities returns in 2022 for its seventh year with approximately 15,000 employees participating in volunteer activities globally to strengthen local communities, expand educational programs and make a positive environmental impact
Week of Possibilities is AbbVie's global, in-person volunteering program that unites employees around the world with a single purpose: to give back to local communities through volunteering